Mankind Pharma Net Profit Drops 21% To ₹558.49 Crore In Q1 FY27
Mankind Pharma Limited reported a 20.69% decline in consolidated net profit for the quarter ended 30 June 2026. Revenue from operations also saw a decrease year-on-year, while total expenses increased
File
Mumbai: Mankind Pharma Limited on Thursday reported a consolidated net profit of ₹558.49 crore for the quarter ended 30 June 2026. This marks a 20.69% decrease compared to ₹704.09 crore in the same quarter last year.
Revenue Performance
The company's consolidated revenue from operations stood at ₹2,964.05 crore for Q1 FY27, down from ₹3,027.67 crore in the corresponding period of the previous fiscal year. Total income for the quarter was ₹2,998.01 crore, a decrease from ₹3,078.69 crore year-on-year.
Expense Overview
Total expenses for the reporting quarter rose to ₹2,241.44 crore, compared to ₹2,138.77 crore in Q1 FY26. Employee benefits expense increased to ₹683.56 crore from ₹592.15 crore in the year-ago quarter.
Earnings Per Share
Basic earnings per share (EPS) for the quarter ended 30 June 2026 was ₹13.53, down from ₹17.06 in Q1 FY26. Diluted EPS also decreased to ₹13.51 from ₹17.04.
Operational Highlights
The board also approved the issuance of a corporate guarantee in favour of Bharat Serums and Vaccines Limited (BSV), a wholly owned subsidiary. Additionally, the company divested its 100% stake in Broadway Hospitality Services Private Limited for ₹49 crore.
Disclaimer: This report is based on the company's filed financial results (standalone or consolidated, as applicable) and is intended solely for informational purposes. It does not constitute investment advice or a recommendation to buy, sell or hold any security.
RECENT STORIES
-
-
-
-
-